REPLIGEN CORPORATION (NASDAQ:RGEN) Files An 8-K Entry into a Material Definitive AgreementItem 1.01.
On February6, 2018, Repligen Corporation, as tenant (the “Company”), and U.S. REIF 111 Locke Drive Massachusetts, LLC, as landlord (the “Landlord”), entered into a Lease Agreement (the “Lease”) with respect to 63,761 square feet of space located at 111 Locke Drive, Marlborough, Massachusetts (the “Premises”).
The term of the Lease commences upon the Company’s substantial completion of the initial buildout of the Premises, but in no event later than June1, 2018 (the “Commencement Date”) and shall continue for a period of 126consecutive months, unless earlier terminated in accordance with the terms of the Lease (the “Lease Term”). Under the Lease, the Company has the option to extend the Lease Term for two additional five year periods.
Fixed rent with respect to 40,000 square feet of the Premises only shall commence on the Commencement Date, and rent for the full 63,761 square feet of the Premises shall begin 19 months following the Commencement Date. The initial fixed rental rate is $9.00 per square foot per annum for the first 12 months, and is subject to additional time-based increases up to a fixed rental rate of $11.50 per square foot per annum at the end of the initial Lease Term. Under the terms of theLease, the Company is required to provide a security deposit of $163,487.50, and will be required to pay its pro rata share of any building operating expenses and real estate taxes.
The Lease is filed as Exhibit 10.1 to this Current Report on Form 8-K, and the above description of the Lease is qualified in its entirety by reference to such exhibit.
|Item 1.01.||Financial Statements and Exhibits.|
REPLIGEN CORP ExhibitEX-10.1 2 d445328dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 LEASE AGREEMENT by and between U.S. REIF 111 LOCKE DRIVE MASSACHUSETTS,…To view the full exhibit click
About REPLIGEN CORPORATION (NASDAQ:RGEN)
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies several growth factor products, Alternating Tangential Flow (ATF) System products and cell filtration products used to increase cell culture productivity during the bioproduction process. The Company has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sells its chromatography columns, as well as media and quality test kits.